Atezolizumab (Tecentriq, Roche) has a marketing authorisation in the UK for 'adult patients with locally advanced or metastatic non‑small cell lung cancer after prior chemotherapy. Patients with EGFR-activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab'.
1,200 mg every 3 weeks by intravenous infusion. The company submission states that patients should have treatment until loss of clinical benefit or unmanageable toxicity.
A 1,200 mg vial costs £3,807.69 excluding VAT (company submission). The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.